A small-sized virus that can hardly be seen with the naked eye, not even ordinary microscopes, and is several times smaller than the human cell. How did this virus beat the immune system? On the other hand, how did the immune system fight this new enemy with a genetic mutation that medicine did not know before? Corona virus is from the new Corona virus family, where most cases of infection appeared in the Chinese city of Wuhan at the end of December 2019 in the form of acute pneumonia. The new Corona virus is believed to be associated with animals, as most of the initial cases were associated with a marine and animal market in Wuhan. Corona viruses can cause a range of symptoms, including fever, cough, shortness of breath, sore throat, and runny nose. Most coronavirus infections cause just the common cold; there are more severe strains that can lead to severe pneumonia that requires hospitalisation. The CDC notes that symptoms of the new coronavirus include "fever and symptoms that affect the interior of the respiratory disease (such as coughing and difficulty breathing)." Risk factors include traveling recently to some affected areas or contacting a person who is suspected of contracting the virus.
The course "The Conflict between Corona Virus and the Human Immune System" discusses these topics, how to prevent this virus and the appropriate treatment mechanism.
Dr. Adeeb Al-Zoubi, molecular immunologist and stem cell scientist. Graduated from the Department of Medical Technology, Southwestern University, Cebu City, Philippines, in 1990. He received his Masters degree in immunohematology from the Department of Clinical Laboratory Sciences, The Chicago Medical School in 1997, where he developed a PCR-based system for genetic screening of beta thalassemia. He was awarded the Ph.D. degree in molecular immunology from the Department of Microbiology and Immunology, The University of Illinois at Chicago, USA, where he identified and characterized the functions of several mRNA splice variants of the human and mouse Map Kinase-Activating Death Domain protein (MADD, IG20) gene, and participated in the sequencing of chromosome 11 as part of the Human Genome Project. Dr. Al-Zoubi worked at Abbott Laboratories headquarters in Illinois, USA, where he was part of a team that developed the first LCR-based system for early and fast detection of Mycobacterium tuberculosis and other infectious substances. Then, he worked as a manager of The Respiratory Cell and Molecular Biology Research Laboratory at The University of Illinois at Chicago, where they worked on the development of novel gene therapy systems for treatment of asthma and smooth muscle diseases. In 2001, Dr. Al-Zoubi joined Miltenyi Biotec as a scientist, where he worked on a novel system for magnetically purifying antigen-specific, cytokine-secreting T lymphocytes in immune therapy of cancers and infectious diseases; he received three shining star excellence awards. Dr. Al-Zoubi moved to The Middle East in 2005, where he formed research and clinical trial groups in Jordan, Egypt, Oman, Syria, and United Arab Emirates, for utilizing stem cells in the treatment of hematological diseases, immune deficiencies, spinal cord injuries, cardiac disorders, and other chronic human diseases. Dr. Al-Zoubi is currently an assistant professor of molecular immunology and stem cells at Philadelphia University in Jordan, a stem cell researcher at the National Center for Diabetes, endocrinology and Genetics in Jordan, a senior stem cell scientist at Halman Neurotherapy Center in Dubai, a stem cell consultant at Sultan Qabus University Hospital in Oman, and a scientific consultant at Miltenyi Biotec, GmbH, Germany. Dr. Al-Zoubi is the founder of Stem Cells of Arabia Network, a council member of the International Association of Neurorestoratology (IANR), a founding member of The International Stem Cell Academy, a member of the International Stem Cell Study Group Association (ISCSG), and the American Association for Cancer Research (AACR).